Ro 47-8634: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6426756 |
| CHEMBL ID | 3956076 |
| SCHEMBL ID | 7796731 |
| MeSH ID | M0331751 |
| Synonym |
|---|
| ro 47-8634 |
| 4-tert-butyl-n-(6-(2-hydroxy-ethoxy)-5-(2-hydroxy-phenoxy)-2,2'-bipyrimidin-4-yl)-benzenesulfonamide |
| 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide |
| FT-0666091 |
| desmethyl bosentan |
| 253688-61-8 |
| SCHEMBL7796731 |
| DTXSID10423786 |
| CHEMBL3956076 , |
| ro-47-8634 |
| AKOS030240417 |
| J-015961 |
| unii-n373r7n42r |
| n373r7n42r , |
| 4-(tert-butyl)-n-(6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)-[2,2'-bipyrimidin]-4-yl)benzenesulfonamide |
| 4-(1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide |
| bdbm50532572 |
| benzenesulfonamide, 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)(2,2'-bipyrimidin)-4-yl)- |
| 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)(2,2'-bipyrimidin)-4-yl)benzenesulfonamide |
| demethoxybosentan |
| bosentan metabolite, ro 47-8634 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The oral bioavailability of bosentan was 43% to 48%, with a small interindividual variability of 20%." | ( Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. Birnboeck, H; Eggers, H; Hopfgartner, G; Jonkman, JH; Meyer, J; Schmitt, R; van Marle, S; Viischer, HW; Weber, C, 1999) | 0.3 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Endothelin-1 receptor | Homo sapiens (human) | IC50 (µMol) | 26.0000 | 0.0000 | 0.7647 | 9.9000 | AID1626367 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| phosphatidylinositol phospholipase C activity | Endothelin-1 receptor | Homo sapiens (human) |
| endothelin receptor activity | Endothelin-1 receptor | Homo sapiens (human) |
| protein binding | Endothelin-1 receptor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Endothelin-1 receptor | Homo sapiens (human) |
| plasma membrane | Endothelin-1 receptor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1323149 | Drug level assessed as human recombinant CYP3A4-mediated compound formation treated with bosentan at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Metabolism study and biological evaluation of bosentan derivatives. |
| AID1323162 | Drug level in human liver microsomes treated with bosentan at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Metabolism study and biological evaluation of bosentan derivatives. |
| AID1323173 | Retention time of the compound | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Metabolism study and biological evaluation of bosentan derivatives. |
| AID1626367 | Displacement of radioligand from ETA receptor (unknown origin) expressed in fall armyworm sf9 cell membranes | 2016 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15 | From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (20.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||